Phase II study to evaluate efficacy and safety of retherapy with bendamustine and rituximab regimens in patients with relapsed/refractory indolent B-cell lymphomas and mantle cell lymphomas
Not Applicable
Recruiting
- Conditions
- relapsed/refractory indolent B-cell lymphomas and mantle cell lymphomas
- Registration Number
- JPRN-UMIN000011152
- Lead Sponsor
- B-SRIM Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who are pregnant or in the location period, and who are not able to, or not willing to prevent conception during the therapeutic period of this clinical study 2. Patients who have coinciding active cancer 3. Patients who have psychiatric disorder 4. Patients who have circulating lymphoma cells >= 25,000 /uL in peripheral blood 5. Patients who have interstitial pneumonia or pulmonary fibrosis 6. Patients who have central nerve system lymphoma 7. Patients who have severe allergic reaction to medication 8. Patients who are considered as inappropriate to register by physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method